SWOG clinical trial number
S9903
A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
Closed
Phase
Accrual
3%
Abbreviated Title
Stereotactic RT Limited Melanoma Brain Mets
Activated
07/15/1999
Closed
06/15/2001
Participants
Research committees
Brain Cancer
Melanoma
Eligibility Criteria Expand/Collapse
Patients must have no more than 3 brain metastases as determined by MRI with no greater than 1 cm separation between images. Patients must have bidimensionally measurable disease; prior histologic confirmation of malignant melanoma, either at the primary site or any metastatic site; patients with any brain lesion greater than 4 cm in maximum dimension, leptomeningeal spread, brain stem lesions or lesions within 5 mm of the optic chiasm are ineligible. If multiple lesions are present and one lesion is > 3 cm, the other lesion(s) must not exceed 3 cm in maximum diameter. Patients must not have received prior radiation , STRS or conventional RT; SWOG PS 0 - 2, prior systemic therapy allowed; patients who have had surgical resection of a brain metastasis must have 1 or 2 other brain mets and/or have measurable residual enhancing disease at the surgical site.
Other Clinical Trials
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase